about
Targeting the PI3K/mTOR axis, alone and in combination with autophagy blockade, for the treatment of malignant peripheral nerve sheath tumorsDevelopment and Notch signaling requirements of the zebrafish choroid plexus.Combining EGFR and mTOR blockade for the treatment of epithelioid sarcomaProgressive loss of myogenic differentiation in leiomyosarcoma has prognostic value.An experimental model for the study of well-differentiated and dedifferentiated liposarcoma; deregulation of targetable tyrosine kinase receptors.Activated MET is a molecular prognosticator and potential therapeutic target for malignant peripheral nerve sheath tumorsPleomorphic liposarcoma: clinical observations and molecular variables.Epithelioid sarcoma and unclassified sarcoma with epithelioid features: clinicopathological variables, molecular markers, and a new experimental model.Dual targeting of mTOR and aurora-A kinase for the treatment of uterine Leiomyosarcoma.Genome-wide in vivo RNAi screen identifies ITIH5 as a metastasis suppressor in pancreatic cancer.Multiple receptor tyrosine kinases promote the in vitro phenotype of metastatic human osteosarcoma cell linesUterine leiomyosarcoma management, outcome, and associated molecular biomarkers: a single institution's experienceSurvivin is a viable target for the treatment of malignant peripheral nerve sheath tumors.MiR-155 is a liposarcoma oncogene that targets casein kinase-1α and enhances β-catenin signaling.Autophagic survival in resistance to histone deacetylase inhibitors: novel strategies to treat malignant peripheral nerve sheath tumors.Targeting the untargetable? Nodal expression in TNBC.Expression of 'drugable' tyrosine kinase receptors in malignant peripheral nerve sheath tumour: potential molecular therapeutic targets for a chemoresistant cancerHeterogeneity and immunophenotypic plasticity of malignant cells in human liposarcomas.INK4a/ARF [corrected] inactivation with activation of the NF-κB/IL-6 pathway is sufficient to drive the development and growth of angiosarcoma.Clinicopathological variables of sporadic schwannomas of peripheral nerve in 291 patients and expression of biologically relevant markers.Histopathologic features of melanoma in difficult-to-diagnose lesions: A case-control study.Automated quantitative image analysis for ex vivo metastasis assays reveals differing lung composition requirements for metastasis suppression by KISS1.Histologic variability in solitary fibrous tumors reflects angiogenic and growth factor signaling pathway alterations.FAP-related desmoid tumors: a series of 44 patients evaluated in a cancer referral centerRevealing retroperitoneal liposarcoma morphology using optical coherence tomography
P50
Q30524134-5E936C24-1A3A-431B-AF9A-6FCEF3242A8CQ33366473-350D431D-1354-43EC-9BCE-ECB7089FA625Q34206363-7DD7814B-6DFA-4089-8258-67F45B130D98Q34588863-ED3B8BFC-CD6A-48A0-A422-4C0C23239ED0Q34682291-9B09294F-C583-4F51-917F-37A57BEE4EF4Q35053276-1695959F-B764-4AB7-BDE0-EC836DD40AE3Q35179511-7BAFC431-8871-4F1C-BC14-C35B7D829BD6Q35584579-E28C69E7-C7F8-40BA-865B-102F8891B9F8Q36205257-2EC4B005-AAA2-4E07-93D7-5F75C6A20C76Q36307011-CAED097F-524E-4984-9410-0911553BE5B5Q36438319-778503F5-BD70-431C-9A81-A3867CA4C88CQ37553880-4E16351A-AD4E-4A51-8D86-A75334802472Q37598765-B63DDC68-B692-4E74-8604-DABD89D83785Q39393414-29C0F37B-9B38-4BDF-91EC-B488B6166E42Q39630633-214DD052-688B-42FB-A4BA-37044624DD52Q42430963-BCC60FFB-6C85-46B0-94B6-E84F7EF7ADC2Q42432919-CAAF779D-CA40-49A0-AB3D-958B688420E1Q42544953-079B47C3-B36D-4767-B7D8-37B46985853DQ42584249-73758DA7-4143-43A1-8FC3-3B30CF511770Q42689177-0601D599-9446-44B8-8F2F-B2C8010A79DCQ47860630-787DE540-30C4-456F-A23F-944780FC6157Q52628893-E72FDF69-626F-4B4C-8168-3ABF83590DF1Q54767173-A07C9FA9-50DA-4C68-AA86-9DC25A221710Q57741127-D54B2AC0-CB78-454C-AC4F-B35002A874ABQ57741166-FAC246E3-F2B7-4D1C-81C3-C9DC286E56F4
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Eric Young
@ast
Eric Young
@en
Eric Young
@es
Eric Young
@nl
Eric Young
@sl
type
label
Eric Young
@ast
Eric Young
@en
Eric Young
@es
Eric Young
@nl
Eric Young
@sl
prefLabel
Eric Young
@ast
Eric Young
@en
Eric Young
@es
Eric Young
@nl
Eric Young
@sl
P106
P21
P31
P496
0000-0002-0014-1482